Understanding Bile Acid Diarrhoea: Expert Guidance on Diagnosis and Treatment

Table of Contents

• Key Points
• Background: What Is Bile Acid Diarrhoea?
• How This Expert Survey Was Conducted
• What Should This Condition Be Called?
• Recognised Associated Conditions
• Symptoms That Point to Bile Acid Diarrhoea
• Diagnostic Tests: How BAD Is Confirmed
• Treatment Decisions and Expected Response Rates
• Medication Doses and Administration
• Follow-Up and Improving Patient Experience
• Expert Discussion: What This Means for Patients
• Study Limitations
• Recommendations for Patients
• Frequently Asked Questions
• Source Information

Key Points

• Bile acid diarrhoea is common but underdiagnosed, often delayed over 5 years.
• SeHCAT is the preferred test; all 21 surveyed experts use it.
• Typical symptoms: frequent loose stools, urgency, and faecal incontinence.
• Bile acid sequestrants work well; severe cases respond in over 70%.
• Ask about BAD if you have diarrhoea after gallbladder removal or ileal surgery.

Background: What Is Bile Acid Diarrhoea?

Bile acids are digestive fluids produced by the liver that help break down fats in the small intestine. Normally, most of these bile acids are reabsorbed in the final section of the small intestine (the terminal ileum) and recycled back to the liver. When this process goes wrong, excess bile acids spill into the colon (large intestine), where they cause water and electrolytes to be secreted into the bowel. The result is a range of distressing digestive symptoms.

This condition has been recognised for over 50 years, originally called "cholerheic enteropathy." Today it is known by several names, including bile acid diarrhoea (BAD), bile acid malabsorption (BAM), and bile salt malabsorption. The scientific understanding has evolved considerably, and the condition is now recognised as far more common than previously thought.

There are two main categories of BAD. Secondary BAD occurs when there is a clear underlying cause, such as:

• Surgical removal of part of the ileum (ileal resection), often for Crohn's disease
• Active Crohn's disease affecting the small intestine
• Cancer chemotherapy
• Pelvic irradiation (radiation therapy to the pelvic area)

Primary or idiopathic BAD occurs when no such cause can be found. This form is common and represents a significant subset of people diagnosed with chronic functional diarrhoea or irritable bowel syndrome with predominant diarrhoea (IBS-D). In most of these patients, there is no actual defect in bile acid absorption. Instead, the problem is that the liver produces too many bile acids. This has been demonstrated by studies showing increased blood levels of a bile acid precursor called 7α-OH-4-cholesten-3-one (abbreviated as C4) and impaired feedback from a hormone called fibroblast growth factor 19 (FGF19), which is produced in the ileum.

One particularly troubling finding from patient surveys is the poor professional recognition of this condition. Many patients experience diagnostic delays exceeding 5 years, enduring persistent symptoms while searching for answers. There is a large unmet need in symptom control, and many patients are left without effective treatment for years.

How This Expert Survey Was Conducted

To establish what current best practice actually looks like, the UK Bile Acid Related Diarrhoea Network (UK-BARDN) was established in 2017 as a forum for researchers who had recently published work on BAD/BAM. The research team identified areas of debate in diagnosis and management and developed a survey consisting of 24 questions.

The survey was distributed online using Survey Monkey at the end of 2018 to 21 clinicians who were members of UK-BARDN. All of these clinicians had published research on BAD. At the time of the survey, 95% held a consultant post in the NHS (the UK's National Health Service); this has since become 100%. A remarkable 100% response rate was achieved.

These were not doctors with casual exposure to the condition. When asked how many patients they had diagnosed with BAD:

• 85% had diagnosed over 50 patients
• 48% had diagnosed more than 100 patients

In total, the survey represents the collective experience of over 20 British gastroenterologists who have treated more than 1,000 patients with BAD. Statistical comparisons were made using Fisher's exact test, with a p value of 0.05 taken as statistically significant.

What Should This Condition Be Called?

The terminology for this condition has varied considerably over the years, which can be confusing for patients encountering different terms in medical records, online information, and consultations. The experts were asked whether there was a preferred term:

• 57% preferred "bile acid diarrhoea" as their first choice
• 14% preferred "bile acid malabsorption"
• 29% used either term depending on the clinical circumstances

When it came to classifying the different types of the condition, 89% preferred the terms "primary or secondary" to describe the cause. The second preference was "types 1, 2 and 3," and the third was "overproduction or malabsorption." This means patients will most likely encounter the terms "primary BAD" (no identifiable underlying cause) or "secondary BAD" (caused by another condition or surgery).

Recognised Associated Conditions

The experts were asked which specific conditions they recognised as being associated with a higher incidence of BAD. The majority identified a wide range of conditions, shown here with the percentage of respondents who recognised each association:

• Ileal resection (surgical removal of part of the ileum)
• Crohn's disease
• Right hemicolectomy (surgical removal of the right side of the colon)
• Cholecystectomy (gallbladder removal)
• Pelvic or abdominal radiotherapy
• Irritable bowel syndrome with predominant diarrhoea (IBS-D)
• Functional bowel disease with diarrhoea
• Microscopic colitis (a type of bowel inflammation visible only under a microscope)
• Bariatric surgery (weight loss surgery)
• Small intestinal bacterial overgrowth (SIBO)
• Partial gastrectomy (surgical removal of part of the stomach)

This list is important for patients because it highlights that BAD can develop after surgery, after cancer treatment, or alongside other digestive conditions. If you have any of these conditions and experience chronic diarrhoea, BAD should be considered as a possible cause.

Symptoms That Point to Bile Acid Diarrhoea

Understanding which symptoms should trigger testing for BAD is critical for improving diagnosis rates. The experts were asked which specific symptoms would lead them to consider a diagnostic test. The results are shown in the table below:

• Always having loose stools – 86% of respondents
• Frequency of bowel movements greater than 6 times per day – 86%
• Frequency of bowel movements 3–6 times per day – 81%
• Intermittent loose stools – 76%
• Faecal urgency at least weekly (the sudden, intense need to reach a toilet) – 67%
• Faecal incontinence at least weekly (accidental leakage of stool) – 62%

Interestingly, the majority of experts said they would not routinely consider testing for BAD based on several other symptoms, including:

• Weight gain or weight loss combined with loose stools
• Variable loose and hard stools
• Anal faecal soiling (minor leakage without full incontinence)
• Bowel frequency of only 1–3 times per day
• Abdominal pain associated with or relieved by defaecation
• Specific yellow or green coloured stools (a commonly repeated belief that did not hold up in expert practice)

These findings are valuable for patients and GPs alike: if you have persistent loose stools multiple times a day, urgency, or incontinence, it is worth discussing BAD testing with your doctor — even if you have been told your symptoms are "just IBS."

Diagnostic Tests: How BAD Is Confirmed

The survey asked experts which diagnostic tests they use for BAD. There was a clear winner: all respondents (100%) selected the SeHCAT test as a diagnostic test for BAD.

What is the SeHCAT test?

The SeHCAT test (tauroselcholic acid scan) uses a small amount of radioactive material — specifically, 75Se-radiolabelled 23-selena-25-homotaurocholate — attached to a synthetic bile acid. This was developed in the 1980s. The patient swallows a capsule containing this substance, and a special gamma camera measures how much of it is retained in the body over 7 days. A low retention rate means bile acids are leaking into the colon instead of being reabsorbed — confirming the diagnosis of BAD.

The SeHCAT test has been shown to predict response to various treatments, including colestyramine, colestipol, colesevelam, a low-fat diet, and even a medication called obeticholic acid. Its use in the UK has grown substantially, particularly in the last decade.

Other diagnostic tests

Blood tests were also recognised as useful diagnostic tools by a majority of experts, though less commonly than SeHCAT:

• FGF19 blood test – recognised by 61%
• C4 blood test – recognised by 57%
• Therapeutic trial (giving treatment to see if symptoms improve) – recognised by 47%

Faecal (stool) bile acid collections are considered unpopular with patients but have been optimised by researchers at the Mayo Clinic in the USA to include the percentage of primary bile acids. It is worth noting that the SeHCAT test is not available in the USA and is not licenced there, which has significantly impaired global understanding and recognition of BAD. This limited availability has also hindered the development of new drugs and formal consensus guidelines. The experts in this survey had limited personal experience with faecal bile acid tests, C4, and FGF19, so these were not major considerations in this survey.

Who should have access to SeHCAT testing?

Having a diagnostic test is one thing; being able to access it is another. The experts were asked about access to SeHCAT, FGF19, C4, and faecal tests in hospitals — all were thought appropriate. However, a striking finding was that only 50% of experts thought that general practitioners (GPs, i.e., family doctors) should have direct access to SeHCAT testing. It was recognised that both hospitals and GPs would also conduct therapeutic trials.

How often is SeHCAT used in different clinical situations?

The survey went beyond simple availability and asked experts how often they would actually request SeHCAT or a therapeutic trial in specific clinical scenarios. The results are detailed in Table 2 of the original paper and summarised below. Experts were asked to classify their use as "always" (>99% of the time), "usually" (>70%), "sometimes" (30–70%), "rarely" (<30%), or "never" (0%).

Functional diarrhoea (diarrhoea without significant abdominal pain or bloating, lasting more than 6 months):

• SeHCAT would be requested usually (more than 70% of the time) by 80% of respondents
• A therapeutic trial would be usually used by only 10%
• This difference was highly statistically significant (p<0.001), meaning it is extremely unlikely to be due to chance

Irritable bowel syndrome with predominant diarrhoea (IBS-D) — more than 25% of stools being Bristol Stool Form Scale (BSFS) type 6/7 in the last 3 months:

• SeHCAT was usually requested by 70% of respondents
• This was significantly more than those who would use a therapeutic trial (p<0.002)

IBS with mixed bowel habit (more than 25% of stools type 6/7 and more than 25% type 1/2):

• SeHCAT was usually requested by 43%
• At least sometimes (more than 30% of the time) by 62%
• Rarely used by 38%

IBS with constipation (fewer than 25% of stools type 6/7, more than 25% type 1/2):

• SeHCAT was rarely used by 50% of respondents

Postcholecystectomy diarrhoea (diarrhoea starting after gallbladder removal):

• SeHCAT was usually used by 71%
• A therapeutic trial was usually used by 36% (p=0.08, a trend but not quite statistically significant)
• When including those who would use the test at least sometimes, SeHCAT was significantly more used than a trial (90% vs 50%, p=0.02)

Crohn's disease with diarrhoea, ileal resection of 50–100 cm, and negative inflammatory markers:

• A therapeutic trial would be used roughly as often as SeHCAT by about half of respondents
• Either test was considered at least sometimes by at least 70% of respondents

Same clinical scenario but with raised inflammatory markers (serum C-reactive protein and faecal calprotectin):

• SeHCAT was used by over 50% at least sometimes
• However, use of a therapeutic trial was much less likely than when inflammatory markers were negative (p=0.02)

This pattern makes clinical sense: when a patient has active Crohn's disease with clear inflammation, doctors are more cautious about giving treatments before confirming the cause of diarrhoea with a formal test.

Treatment Decisions and Expected Response Rates

Once BAD is confirmed, what happens next? The experts were asked about the likelihood of offering treatment (with bile acid sequestrants) based on the patient's SeHCAT result. The results are striking and clinically important.

SeHCAT results are reported as the percentage of radioactive bile acid retained at 7 days. Lower retention means more severe bile acid leakage. The expert approach was:

• Severe disease (SeHCAT retention 0–5%): All respondents (100%) would always treat these patients
• Moderate disease (SeHCAT 5–10%): 86% would always treat; the rest would usually treat
• Mild disease (SeHCAT 10–15%): 86% would usually treat
• Borderline (SeHCAT 15–20%): 80% would sometimes offer treatment
• Normal (SeHCAT >20%): Treatment was rarely offered

Predicted response rates to treatment

The experts were also asked what response rate they would expect following optimisation of bile acid sequestrant (BAS) therapy for each SeHCAT category. The predicted response rate varied inversely with SeHCAT values — meaning the lower the retention, the better the expected response. The full distribution is shown below:

• SeHCAT 0–5%: 53% of experts predicted ≥90% response; 48% predicted 70–90% response
• SeHCAT 5–10%: 24% predicted ≥90% response; 58% predicted 70–90% response; 14% predicted 50–70%; 5% predicted <30%
• SeHCAT 10–15%: 5% predicted ≥90%; 14% predicted 70–90%; 48% predicted 50–70%; 29% predicted 30–50%; 5% predicted <30%
• SeHCAT 15–20%: 10% predicted 50–70%; 45% predicted 30–50%; 45% predicted <30%
• SeHCAT >20%: 100% of experts predicted a <30% response rate

In plain terms: patients with the most severe BAD (lowest SeHCAT retention) have the highest likelihood of responding well to treatment. Expected response rates for severe disease exceed 70% in the most affected patients. Even those with mild disease (10–15% retention) have a reasonable chance of improvement, with most experts predicting a 50–70% response rate. This is important encouragement for patients considering testing.

Medication Doses and Administration

Bile acid sequestrants (BAS) are the mainstay of treatment for BAD. These medications bind to bile acids in the intestine, preventing them from causing fluid secretion in the colon. The survey provided detailed information about prescribing practices.

Which medication is used first?

Colestyramine was the first-line BAS used by 95% of respondents. This is a powder that is mixed with water or juice. Colesevelam was the second choice, and colestipol was also mentioned. Colesevelam comes in tablet form, making it more acceptable to many patients, but it remains the second choice. The experts recognised the importance of trying an alternative BAS if the first one produces an incomplete response.

Starting doses for colestyramine

For a typical patient weighing 70 kg, the starting dose of colestyramine varied considerably among experts:

• 29% started at 2 g once daily
• 38% started at 4 g once daily
• 24% started at 4 g twice daily
• 10% started at 4 g three times daily

Starting doses for colesevelam

• 29% started at 625 mg once daily
• 24% started at 1.25 g once daily
• 29% started at 1.25 g twice daily
• 10% started at 1.25 g three times daily (or another regimen)

Timing of medication

There was a preference to give these drugs last thing at night (38% of respondents) rather than with food (29%). This is worth discussing with your doctor if you find your current timing is not working well. Additionally, 76% of experts usually gave warnings to take other medications 1 hour before or 4 hours after the BAS, in order to avoid interactions. This is particularly important because bile acid sequestrants can bind to other medications and reduce their absorption.

What if the response is incomplete?

Many patients experience some improvement but not complete resolution of symptoms. The experts were unanimous in their approach to this situation. When patients had an incomplete response, the following recommendations were common:

• Increasing the dose – recommended by 100% of respondents
• Increasing use of drugs such as loperamide (Imodium, an anti-diarrhoeal medication) – recommended by 80%
• Changing to an alternative BAS (e.g., colesevelam or colestipol) – recommended by 71%
• Advice on a low-fat diet (40 g/day) – recommended by 71%
• Avoidance of high FODMAP foods – recommended by 29%

Notably, there was little difference in these recommendations whether the patient had a SeHCAT result of 3% or 13%. In other words, the same stepwise treatment strategy applies across the range of BAD severity.

Follow-Up and Improving Patient Experience

The survey also asked about follow-up care for a typical patient being treated with a BAS. The following approaches were given broadly similar importance by the experts:

• Annual review by a specialist (gastroenterologist) or GP
• Patient support groups
• Dietetic review (consulting a registered dietitian)
• Pharmacist review
• Monitoring of blood vitamins and lipids (because bile acid sequestrants can affect absorption of fat-soluble vitamins and cholesterol levels)

These are practical points that patients can raise at their next appointment. If you are taking a BAS long-term, asking your doctor about annual blood tests for vitamins and lipid levels is a reasonable step.

Improving the overall patient experience

Experts were asked what would most improve the patient experience for people with BAD. The majority considered all of the following important:

• Greater recognition of BAD by various professional groups, particularly gastroenterologists
• Greater recognition in the popular press
• Greater recognition by GPs
• Improved diagnosis
• Improved drugs for treating the condition

This reinforces the message that awareness is one of the biggest barriers to patients receiving timely, effective care.

Expert Discussion: What This Means for Patients

The experts discuss several important implications of their findings.

First, the need for SeHCAT testing is strongly supported. The survey clearly demonstrates that making a formal diagnosis with SeHCAT testing is the preferred approach. Only in one specific patient group — those with Crohn's disease, ileal resection, and negative inflammatory markers — did a therapeutic trial of treatment receive support similar to SeHCAT testing. This makes sense because accumulated data shows that more than 90% of these patients are likely to have an abnormal SeHCAT result. The limited support for therapeutic trials elsewhere indicates that doctors value obtaining a clear diagnosis before starting treatment, rather than simply trying treatment and seeing what happens.

Second, awareness of BAD in functional bowel disorders is growing. The latest Rome IV guidance (the internationally recognised criteria for diagnosing functional gastrointestinal disorders) now includes consideration of BAD in functional bowel disorders with diarrhoea. The experts in this survey provide concrete data supporting this: they consider SeHCAT testing usually necessary in patients who meet criteria for functional diarrhoea and IBS-D. They also sometimes recommend it for patients with IBS and mixed bowel habits.

Third, there are significant economic advantages to early diagnosis. Recent studies have shown that diagnosing BAD early with SeHCAT testing reduces unnecessary investigations — particularly cross-sectional imaging (such as CT scans), repeated colonoscopies, and unnecessary trials of expensive medications. This is good news for healthcare systems and for patients who might otherwise undergo a long and uncomfortable diagnostic journey.

Fourth, the international availability of SeHCAT is a major issue. The rates of BAD are likely similar worldwide, but the SeHCAT test is only available in certain countries and is not licenced in the USA. This has "greatly impaired the understanding of its value," as the authors note, and has hindered recognition of BAD, development of new drugs, and formulation of consensus guidelines. If SeHCAT licensing cannot be extended, alternative tests such as 48-hour faecal bile acid measurements, C4, and FGF19 will require further development and validation. The work at the Mayo Clinic on faecal primary bile acid measurement is an interesting development related to bile acid secretion and absorption.

Fifth, there is a role for blood tests in the diagnostic pathway. Previous findings suggest that low C4 and high FGF19 levels both have good negative predictive value (meaning normal results help rule out BAD) and may help select patients for further testing. However, the SeHCAT test has a unique advantage: because it measures retention over 7 days, it integrates multiple cycles of bile acid secretion and reabsorption, making it less affected by day-to-day variation and dietary effects.

Finally, treatment approaches are well established. Bile acid sequestrants, particularly colestyramine, are the mainstay of treatment. Good response rates are predicted in patients with severe disease. Starting with a low dose, giving the medication last thing at night, and considering a low-fat diet (40 g/day) to help reduce symptoms are all recommended strategies. Alternative drug therapies and diets become particularly relevant when the medication supply is interrupted — an issue that many patients have experienced during periods of drug shortage.

Study Limitations

It is important to understand the limitations of this research. The study reflects opinion only, not direct evidence from clinical trials. It is also limited geographically to the UK, where there is greater use of SeHCAT testing and thus greater experience in BAD diagnosis and management than in most other countries.

There is a possibility that other UK gastroenterologists who were not part of this network may have different views. However, the fact that all respondents had published research on BAD and had diagnosed large numbers of patients (most over 50, nearly half over 100) gives substantial weight to their collective opinion, particularly where there was strong consensus.

Additionally, the experts' experience with newer tests (faecal bile acids, C4, FGF19) was limited, so these were not major considerations in the survey. The cost-effectiveness of various diagnostic strategies was also not directly assessed, although the experts note that published studies show economic advantages to early SeHCAT testing.

Recommendations for Patients

Based on this expert survey, here is what patients should know and consider:

1. If you have chronic diarrhoea, don't accept "it's just IBS" without exploring further. BAD is a common cause of symptoms in people diagnosed with IBS-D or functional diarrhoea. If you have frequent loose stools (more than 3 times a day), urgency, or faecal incontinence, ask your doctor whether bile acid diarrhoea has been considered.
2. SeHCAT testing is the gold standard for diagnosis. It is a relatively simple test: you swallow a capsule and have a scan over 7 days. If it is not available at your hospital, ask about blood tests (FGF19, C4) or a therapeutic trial. However, be aware that a formal diagnosis is preferred before starting long-term treatment.
3. If you have had your gallbladder removed, prostate or abdominal radiation, ileal surgery, or weight loss surgery, and you now have diarrhoea, BAD is a strong possibility and testing should be considered.
4. Treatment works. If your SeHCAT test is positive, the chance of improvement with bile acid sequestrant therapy is high — over 70% in the most severely affected patients. Even patients with mild BAD (10–15% retention) have a reasonable chance of improvement.
5. Bile acid sequestrants require patience and optimisation. Your doctor may start with a low dose and increase it gradually. If one medication does not work well, ask about switching to another. Taking the medication last thing at night can help. Take other medications either 1 hour before or 4 hours after the BAS to avoid interactions.
6. A low-fat diet (around 40 g of fat per day) can help reduce symptoms and is worth discussing with a dietitian, particularly if you have an incomplete response to medication alone.
7. Ask for annual follow-up. Long-term monitoring of vitamin levels and lipids is reasonable, and regular review with a specialist, GP, or pharmacist can help optimise your treatment and overall experience.
8. Consider patient support groups. These were valued by experts as part of the overall patient experience. Connecting with others who have BAD can provide practical advice and emotional support.

Frequently Asked Questions

What is bile acid diarrhoea (BAD) and why is it often missed?

BAD occurs when excess bile acids spill into the colon, causing watery diarrhoea, urgency, and incontinence. It is underdiagnosed because symptoms mimic irritable bowel syndrome, and many patients experience delays over five years. Experts recommend considering BAD in anyone with chronic loose stools, especially after gallbladder removal, ileal surgery, or radiation.

How is bile acid diarrhoea diagnosed?

The SeHCAT test is the preferred diagnostic tool, used by all 21 experts surveyed. You swallow a capsule with a radioactive tracer, and a scan measures retention over 7 days. Retention below 15% confirms BAD. Blood tests (FGF19, C4) and therapeutic trials are also used, but SeHCAT is the gold standard where available.

What symptoms should make me ask my doctor about bile acid diarrhoea?

Experts would test for BAD if you always have loose stools, pass stools more than 3 times daily, have intermittent loose stools, or experience weekly urgency or faecal incontinence. They would not test based on stool colour alone. If you have these symptoms and a history of gallbladder removal, ileal resection, or IBS-D, ask about BAD.

How effective is treatment for bile acid diarrhoea?

Bile acid sequestrants are highly effective. In patients with severe BAD (SeHCAT retention 0–5%), over 70% of experts predicted a 70–90% or higher response. Even mild cases (10–15% retention) had predicted response rates of 50–70%. Treatment requires dose optimisation and sometimes switching medications or adding a low-fat diet.

What is the first-line medication for bile acid diarrhoea and how is it taken?

Colestyramine was the first-line treatment for 95% of experts. It is a powder mixed with water or juice. Starting doses varied, but many prefer giving it last thing at night. If symptoms persist, experts recommend increasing the dose, adding loperamide, switching to colesevelam or colestipol, or trying a 40 g/day low-fat diet.

Can bile acid diarrhoea occur after gallbladder removal or other surgeries?

Yes. Experts recognised BAD as associated with cholecystectomy (gallbladder removal), ileal resection, right hemicolectomy, bariatric surgery, and partial gastrectomy. If you develop chronic diarrhoea after any of these procedures, ask your doctor whether BAD testing, such as SeHCAT, is appropriate. Treatment can greatly improve symptoms.

What follow-up care is recommended for people taking bile acid sequestrants?

Experts support annual review by a specialist or GP, dietetic review, pharmacist review, and monitoring of blood vitamins and lipids, since sequestrants can affect absorption. They also value patient support groups. Ask your doctor about annual blood tests and review appointments to optimise long-term management.

When should a patient with suspected bile acid diarrhoea seek a second opinion?

If you have chronic diarrhoea and have been told it is just IBS, or if you have had symptoms for years without a clear diagnosis, a second opinion can help. Experts recommend considering bile acid diarrhoea (BAD) in anyone with frequent loose stools, urgency, or incontinence, especially after gallbladder removal or ileal surgery. The SeHCAT test is the preferred diagnostic tool, and treatment with bile acid sequestrants is effective in over 70% of severe cases. Diagnostic Detectives Network provides independent expert second opinions.

Source Information

Original article title: Diagnosis and management of bile acid diarrhoea

Authors: Julian R F Walters, Ramesh Arasaradnam, H Jervoise N Andreyev, for the UK Bile Acid Related Diarrhoea Network

Publication: Frontline Gastroenterology, 2020; volume 11, pages 358–363. doi:10.1136/flgastro-2019-101301

Received: 27 July 2019 | Revised: 16 August 2019 | Accepted: 2 September 2019 | Published online: 11 September 2019

Funding: The authors declared no specific grant for this research from any funding agency in the public, commercial, or not-for-profit sectors.

Note: This patient-friendly article is based on peer-reviewed research. It is intended for educational purposes and does not replace individual medical advice. Always consult your healthcare provider about your specific condition and treatment options.